Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Analyst Outlook | JMP Securities maintains a Market Outperform rating with a $7 price target, while other analysts adopt a cautious stance amid early-stage developments |
Market Potential | Explore RLYB116's target indications, representing a $5B market opportunity in rare diseases with limited competition and high unmet needs |
Financial Fortitude | With $46M cash runway into mid-2027, Rallybio demonstrates fiscal discipline amid pipeline transitions, boasting a strong current ratio of 9.98x |
Pipeline Pivot | Rallybio shifts focus to RLYB116, a C5 inhibitor, after discontinuing its lead FNAIT program, reshaping its development strategy and market position |
Metrics to compare | RLYB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLYBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.0x | −2.5x | −0.5x | |
PEG Ratio | −0.06 | 0.10 | 0.00 | |
Price / Book | 0.8x | 2.6x | 2.6x | |
Price / LTM Sales | 52.4x | 28.3x | 3.2x | |
Upside (Analyst Target) | −6.4% | 86.5% | 45.2% | |
Fair Value Upside | Unlock | 14.9% | 6.4% | Unlock |